News | July 15, 2022
Syngene signs 10-year biologics manufacturing agreement with Zoetis
Syngene's collaboration with Zoetis started in 2011
Syngene's collaboration with Zoetis started in 2011
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
Subscribe To Our Newsletter & Stay Updated
